Shares of Kodiak Sciences plunged by over 50% in premarket trading on Monday as the biopharmaceutical company announced the termination of its lead investigational medicine, tarcocimab tedromer. This decision comes after the failure of two Phase 3 studies focusing on the treatment of diabetic macular edema. Disappointing Results in Phase 3 Studies Kodiak Sciences, headquartered … [Read more...] about Kodiak Sciences Ends Development of Lead Investigational Medicine
Footer
